140 related articles for article (PubMed ID: 16809922)
1. Dopaminergic D2 receptor knockout mouse: an animal model of prolactinoma.
Cristina C; García-Tornadú I; Díaz-Torga G; Rubinstein M; Low MJ; Becú-Villalobos D
Front Horm Res; 2006; 35():50-63. PubMed ID: 16809922
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
Luque GM; Perez-Millán MI; Ornstein AM; Cristina C; Becu-Villalobos D
J Pharmacol Exp Ther; 2011 Jun; 337(3):766-74. PubMed ID: 21406548
[TBL] [Abstract][Full Text] [Related]
3. Increased pituitary vascular endothelial growth factor-a in dopaminergic D2 receptor knockout female mice.
Cristina C; Díaz-Torga G; Baldi A; Góngora A; Rubinstein M; Low MJ; Becú-Villalobos D
Endocrinology; 2005 Jul; 146(7):2952-62. PubMed ID: 15817666
[TBL] [Abstract][Full Text] [Related]
4. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast growth factor-2 in hyperplastic pituitaries of D2R knockout female mice.
Cristina C; Díaz-Torga G; Góngora A; Guida MC; Perez-Millán MI; Baldi A; Becu-Villalobos D
Am J Physiol Endocrinol Metab; 2007 Nov; 293(5):E1341-51. PubMed ID: 17848635
[TBL] [Abstract][Full Text] [Related]
6. Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice.
Asa SL; Kelly MA; Grandy DK; Low MJ
Endocrinology; 1999 Nov; 140(11):5348-55. PubMed ID: 10537166
[TBL] [Abstract][Full Text] [Related]
7. GH in the dwarf dopaminergic D2 receptor knockout mouse: somatotrope population, GH release, and responsiveness to GH-releasing factors and somatostatin.
García-Tornadú I; Rubinstein M; Gaylinn BD; Hill D; Arany E; Low MJ; Díaz-Torga G; Becu-Villalobos D
J Endocrinol; 2006 Sep; 190(3):611-9. PubMed ID: 17003262
[TBL] [Abstract][Full Text] [Related]
8. Ovarian dependence for pituitary tumorigenesis in D2 dopamine receptor-deficient mice.
Hentges ST; Low MJ
Endocrinology; 2002 Dec; 143(12):4536-43. PubMed ID: 12446580
[TBL] [Abstract][Full Text] [Related]
9. Laminin inhibits lactotroph proliferation and is reduced in early prolactinoma development.
Kuchenbauer F; Theodoropoulou M; Hopfner U; Stalla J; Renner U; Tonn JC; Low MJ; Arzt E; Stalla GK; Páez-Pereda M
Mol Cell Endocrinol; 2003 Sep; 207(1-2):13-20. PubMed ID: 12972179
[TBL] [Abstract][Full Text] [Related]
10. Activin-inhibitory action on lactotrophs is decreased in lactotroph hyperplasia.
Faraoni EY; Abeledo Machado AI; Pérez PA; Marcial López CA; Camilletti MA; Peña-Zanoni M; Rulli SB; Gutiérrez S; Díaz-Torga G
J Endocrinol; 2020 Feb; 244(2):415-429. PubMed ID: 32395971
[TBL] [Abstract][Full Text] [Related]
11. Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells.
Ben-Shlomo A; Miklovsky I; Ren SG; Yong WH; Heaney AP; Culler MD; Melmed S
J Clin Endocrinol Metab; 2003 Feb; 88(2):858-63. PubMed ID: 12574225
[TBL] [Abstract][Full Text] [Related]
12. New insights into the endocrine and metabolic roles of dopamine D2 receptors gained from the Drd2 mouse.
Garcia-Tornadú I; Perez-Millan MI; Recouvreux V; Ramirez MC; Luque G; Risso GS; Ornstein AM; Cristina C; Diaz-Torga G; Becu-Villalobos D
Neuroendocrinology; 2010; 92(4):207-14. PubMed ID: 20975260
[TBL] [Abstract][Full Text] [Related]
13. Sex differences in the pituitary transforming growth factor-β1 system: studies in a model of resistant prolactinomas.
Recouvreux MV; Lapyckyj L; Camilletti MA; Guida MC; Ornstein A; Rifkin DB; Becu-Villalobos D; Díaz-Torga G
Endocrinology; 2013 Nov; 154(11):4192-205. PubMed ID: 24008346
[TBL] [Abstract][Full Text] [Related]
14. Disruption of the D2 dopamine receptor alters GH and IGF-I secretion and causes dwarfism in male mice.
Díaz-Torga G; Feierstein C; Libertun C; Gelman D; Kelly MA; Low MJ; Rubinstein M; Becú-Villalobos D
Endocrinology; 2002 Apr; 143(4):1270-9. PubMed ID: 11897683
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis in prolactinomas: regulation and relationship with tumour behaviour.
de la Torre NG; Turner HE; Wass JA
Pituitary; 2005; 8(1):17-23. PubMed ID: 16411064
[TBL] [Abstract][Full Text] [Related]
16. Filamin-A is essential for dopamine d2 receptor expression and signaling in tumorous lactotrophs.
Peverelli E; Mantovani G; Vitali E; Elli FM; Olgiati L; Ferrero S; Laws ER; Della Mina P; Villa A; Beck-Peccoz P; Spada A; Lania AG
J Clin Endocrinol Metab; 2012 Mar; 97(3):967-77. PubMed ID: 22259062
[TBL] [Abstract][Full Text] [Related]
17. Pituitary tumorigenesis in prolactin gene-disrupted mice.
Cruz-Soto ME; Scheiber MD; Gregerson KA; Boivin GP; Horseman ND
Endocrinology; 2002 Nov; 143(11):4429-36. PubMed ID: 12399440
[TBL] [Abstract][Full Text] [Related]
18. Expression of Stem Cell Markers and Dopamine D2 Receptors in Human and Rat Prolactinomas.
Gao Z; Cai L; Lu J; Wang C; Li Q; Chen J; Song X; Chen X; Zhang L; Zheng W; Su Z
Med Sci Monit; 2017 Apr; 23():1827-1833. PubMed ID: 28411401
[TBL] [Abstract][Full Text] [Related]
19. Selective disruption of dopamine D2 receptors in pituitary lactotropes increases body weight and adiposity in female mice.
Perez Millan MI; Luque GM; Ramirez MC; Noain D; Ornstein AM; Rubinstein M; Becu-Villalobos D
Endocrinology; 2014 Mar; 155(3):829-39. PubMed ID: 24424036
[TBL] [Abstract][Full Text] [Related]
20. Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms.
Schuff KG; Hentges ST; Kelly MA; Binart N; Kelly PA; Iuvone PM; Asa SL; Low MJ
J Clin Invest; 2002 Oct; 110(7):973-81. PubMed ID: 12370275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
